Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects
Status:
Suspended
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This study has two parts. Part A will assess the safety, tolerability and pharmacokinetics
(PK) of AT-777 in healthy subjects. Part B will assess the safety, antiviral
activity/efficacy and PK of AT-777 in combination with AT-527 after 8 weeks of treatment in
HCV-infected subjects.